Nov 21, 2019
FDA approves new treatment for adults with partial-onset seizures
Nov 13, 2019
Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology
May 09, 2019
Lower Hospitalization Rates In Epilepsy Patients Treated With Adjunctive FYCOMPA® (perampanel) CIII
Dec 04, 2018
New Analyses Evaluate Long-Term Convulsive Seizure Freedom Rates With Use Of Adjunctive FYCOMPA® (perampanel) CIII In Adult Patients Presented at Annual Meeting of the American Epilepsy Society (AES)
Nov 30, 2018
UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership
Oct 30, 2018
UCB First Nine Months Interim Report 2018: UCB tracking well towards full year financial outlook
May 30, 2018
Eisai Receives FDA Priority Review Designation for FYCOMPA® (perampanel) CIII Pediatric Indications Supplemental New Drug Application (sNDA)
May 14, 2018
UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients
Nov 06, 2017
UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
Sep 15, 2017
New indication for BRIVIACT® (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults
Jul 26, 2017
FDA Approves Eisai's FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures